LON:BPCR BioPharma Credit (BPCR) Share Price, News & Analysis GBX 0.85 +0.01 (+1.43%) As of 07:54 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsDividendInsider TradesBuy This Stock About BioPharma Credit Stock (LON:BPCR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BioPharma Credit alerts:Sign Up Key Stats Today's Range 0.83▼ 0.8550-Day Range 0.80▼ 0.8952-Week Range 0.80▼ 0.94Volume251,505 shsAverage Volume976,453 shsMarket Capitalization£1.01 billionP/E Ratio9.68Dividend Yield821.60%Price TargetN/AConsensus RatingN/A Company OverviewBioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. Its debt assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. The company was incorporated in 2016 and is based in London, the United Kingdom.Read More… Remove Ads Receive BPCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioPharma Credit and its competitors with MarketBeat's FREE daily newsletter. Email Address BPCR Stock News HeadlinesCash in on the biotech sector with specialist trust BioPharmaApril 3, 2025 | msn.comBioPharma Credit announces dividend payoutJanuary 23, 2025 | msn.comThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside and write a book about it. This isn't just another Bitcoin prediction – it's a complete roadmap for what I believe will be the biggest wealth-building opportunity of this decade. The evidence is so compelling, I'm doing something that probably seems insane: I'm giving away my entire book for free. April 16, 2025 | Crypto 101 Media (Ad)BioPharma Credit's (LON:BPCR) investors will be pleased with their respectable 43% return over the last five yearsJanuary 7, 2025 | finance.yahoo.comInvestors in BioPharma Credit (LON:BPCR) have seen respectable returns of 44% over the past five yearsAugust 1, 2024 | finance.yahoo.comBuy Rating Affirmed for Benitec Biopharma Following Promising BB-301 Trial Results and Financial BoostApril 22, 2024 | markets.businessinsider.comBioPharma Credit PLC (BPCP.L)February 26, 2024 | nz.finance.yahoo.comInvestors in BioPharma Credit (LON:BPCR) have seen notable returns of 40% over the past five yearsFebruary 22, 2024 | finance.yahoo.comSee More Headlines BPCR Stock Analysis - Frequently Asked Questions How have BPCR shares performed this year? BioPharma Credit's stock was trading at GBX 0.88 at the start of the year. Since then, BPCR shares have decreased by 3.6% and is now trading at GBX 0.85. View the best growth stocks for 2025 here. How do I buy shares of BioPharma Credit? Shares of BPCR stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of BioPharma Credit own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioPharma Credit investors own include AFPO.L (AFPO), Altius Minerals (ATUSF), LiDCO Group Plc (LID.L) (LID), NexGen Energy (NXE), Peninsula Energy (PEN), Premier African Minerals (PREM) and 21512 (SAT.L) (SAT). Company Calendar Record date for 3/13 Dividend2/06/2025Ex-Dividend for 3/13 Dividend2/06/2025Dividend Payable3/13/2025Record date for 5/7 Dividend4/03/2025Ex-Dividend for 5/7 Dividend4/03/2025Today4/16/2025Dividend Payable5/07/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorFinancial Services Industry Asset Management Sub-IndustryN/A Current SymbolLON:BPCR CIKN/A Webwww.bpcruk.com Phone44 13 9247 7500FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX 0.09 Trailing P/E Ratio9.68 Forward P/E RatioN/A P/E GrowthN/ANet Income£10.42 billion Net Margins80.20% Pretax MarginN/A Return on Equity8.51% Return on Assets4.98% Debt Debt-to-Equity RatioN/A Current Ratio21.50 Quick Ratio14.07 Sales & Book Value Annual Sales£12.99 billion Price / Sales0.08 Cash FlowGBX 0.71 per share Price / Cash Flow1.19 Book ValueGBX 98.56 per share Price / Book0.01Miscellaneous Outstanding Shares118,721,336,824Free FloatN/AMarket Cap£1.01 billion OptionableNot Optionable Beta0.22 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (LON:BPCR) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioPharma Credit Please log in to your account or sign up in order to add this asset to your watchlist. Share BioPharma Credit With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
